<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38235145</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>T4 apoptosis in the acute phase of SARS-CoV-2 infection predicts long COVID.</ArticleTitle><Pagination><StartPage>1335352</StartPage><MedlinePgn>1335352</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1335352</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1335352</ELocationID><Abstract><AbstractText Label="BACKGROUND">As about 10% of patients with COVID-19 present sequelae, it is important to better understand the physiopathology of so-called long COVID.</AbstractText><AbstractText Label="METHOD">To this aim, we recruited 29 patients hospitalized for SARS-CoV-2 infection and, by Luminex<sup>&#xae;</sup>, quantified 19 soluble factors in their plasma and in the supernatant of their peripheral blood mononuclear cells, including inflammatory and anti-inflammatory cytokines and chemokines, Th1/Th2/Th17 cytokines, and endothelium activation markers. We also measured their T4, T8 and NK differentiation, activation, exhaustion and senescence, T cell apoptosis, and monocyte subpopulations by flow cytometry. We compared these markers between participants who developed long COVID or not one year later.</AbstractText><AbstractText Label="RESULTS">None of these markers was predictive for sequelae, except programmed T4 cell death. T4 lymphocytes from participants who later presented long COVID were more apoptotic in culture than those of sequelae-free participants at Month 12 (36.9 &#xb1; 14.7 vs. 24.2 &#xb1; 9.0%, p&#xa0;= 0.016).</AbstractText><AbstractText Label="CONCLUSIONS">Our observation raises the hypothesis that T4 cell death during the acute phase of SARS-CoV-2 infection might pave the way for long COVID. Mechanistically, T4 lymphopenia might favor phenomena that could cause sequelae, including SARS-CoV-2 persistence, reactivation of other viruses, autoimmunity and immune dysregulation. In this scenario, inhibiting T cell apoptosis, for instance, by caspase inhibitors, could prevent long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Cezar, Kundura, Andr&#xe9;, Lozano, Vincent, Muller, Lefrant, Roger, Claret, Duvnjak, Loubet, Sotto, Tran, Estaquier and Corbeau.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cezar</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Immunology Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kundura</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, UMR9002, Centre National de la Recherche Scientifique (CNRS) and Montpellier University, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andr&#xe9;</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM) U1124, Universit&#xe9; de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lozano</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Immunology Department, Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Immunology Department, Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muller</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefrant</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roger</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claret</LastName><ForeName>Pierre-G&#xe9;raud</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Medical and Surgical Emergency Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duvnjak</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gerontology Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loubet</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotto</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Tu-Ahn</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Pediatrics Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Estaquier</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM) U1124, Universit&#xe9; de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laval University Research Center, Quebec City, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Corbeau</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Immunology Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Human Genetics, UMR9002, Centre National de la Recherche Scientifique (CNRS) and Montpellier University, Montpellier, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 infection sequelae</Keyword><Keyword MajorTopicYN="N">helper T lymphocyte</Keyword><Keyword MajorTopicYN="N">immune activation</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">programmed cell death</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>18</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38235145</ArticleId><ArticleId IdType="pmc">PMC10791767</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1335352</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. . Short-term and long-term rates of postacute sequelae of SARS-coV-2 infection: A systematic review. JAMA Netw Open (2021) 4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent symptoms in patients after acute COVID-19. JAMA (2020) 324:603&#x2013;5. doi: 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>
Anonymous . Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>
Anonymous . Available at: https://covid19.who.int/.</Citation></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: A systematic review. JAMA Netw Open (2021) 4:e2111417. doi: 10.1001/jamanetworkopen.2021.11417</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya AA, Akbari A, Emami A, Lotfi M, Rostamihosseinkhani M, Nemati H, et al. . Risk factors associated with long COVID syndrome: A retrospective study. Iran J Med Sci (2021) 46:428&#x2013;36. doi:&#xa0;10.30476/ijms.2021.92080.2326</Citation><ArticleIdList><ArticleId IdType="doi">10.30476/ijms.2021.92080.2326</ArticleId><ArticleId IdType="pmc">PMC8611223</ArticleId><ArticleId IdType="pubmed">34840383</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. . Risk factors associated with post-COVID-19 condition: A systematic review and meta-analysis. JAMA Intern Med (2023) 183:566&#x2013;80. doi: 10.1001/jamainternmed.2023.0750</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ, Halim A, Halim M, Liu S, Aljeldah M, Al Shammari BR, et al. . Inflammatory and vascular biomarkers in post-COVID-19 syndrome: A systematic review and meta-analysis of over 20 biomarkers. Rev Med Virol (2023) 33:e2424. doi: 10.1002/rmv.2424</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2424</ArticleId><ArticleId IdType="pubmed">36708022</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa Cruz A, Mendes-Frias A, Azarias-da-Silva M, Andre S, Oliveira AI, Pires O, et al. . Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8(+)beta7 integrin(+) T cells and anti-SARS-CoV-2 IgA response. Nat Commun (2023) 14:1772. doi: 10.1038/s41467-023-37368-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37368-1</ArticleId><ArticleId IdType="pmc">PMC10061413</ArticleId><ArticleId IdType="pubmed">36997530</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin JX, Agbana YL, Sun ZS, Fei SW, Zhao HQ, Zhou XN, et al. . Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis. Infect Dis Poverty (2023) 12:43. doi: 10.1186/s40249-023-01086-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-023-01086-z</ArticleId><ArticleId IdType="pmc">PMC10123579</ArticleId><ArticleId IdType="pubmed">37095536</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlefield KM, Watson RO, Schneider JM, Neff CP, Yamada E, Zhang M, et al. . SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PloS Pathog (2022) 18:e1010359. doi: 10.1371/journal.ppat.1010359</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010359</ArticleId><ArticleId IdType="pmc">PMC9176759</ArticleId><ArticleId IdType="pubmed">35617421</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortellini A, Gennari A, Pommeret F, Patel G, Newsom-Davis T, Bertuzzi A, et al. . COVID-19 sequelae and the host proinflammatory response: an analysis from the onCovid registry. J Natl Cancer Inst (2022) 114:979&#x2013;87. doi: 10.1093/jnci/djac057</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djac057</ArticleId><ArticleId IdType="pmc">PMC9047221</ArticleId><ArticleId IdType="pubmed">35417006</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Sans HM, Forman CA, Nylander AN, Ho HE, Lu S, et al. . Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-coV-2 infection. Neurol Neuroimmunol Neuroinflamm (2022) 9 (5):e200003. doi: 10.1212/NXI.0000000000200003</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200003</ArticleId><ArticleId IdType="pmc">PMC9210548</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol (2022) 23:210&#x2013;6. doi: 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell (2022) 185:881&#x2013;895 e20. doi: 10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Guevara-Coto J, Yogendra R, Francisco EB, Long E, Pise A, et al. . Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front Immunol (2021) 12:700782. doi: 10.3389/fimmu.2021.700782</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.700782</ArticleId><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Tang L, Ma Y, Li Y, Zhang D, Li Q, et al. . Immunological profiling of COVID-19 patients with pulmonary sequelae. mBio (2021) 12:e0159921. doi: 10.1128/mBio.01599-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01599-21</ArticleId><ArticleId IdType="pmc">PMC8546863</ArticleId><ArticleId IdType="pubmed">34488453</ArticleId></ArticleIdList></Reference><Reference><Citation>Andre S, Picard M, Cezar R, Roux-Dalvai F, Alleaume-Butaux A, Soundaramourty C, et al. . T cell apoptosis characterizes severe Covid-19 disease. Cell Death Differ (2022) 29 (8):1486&#x2013;99. doi:&#xa0;10.1038/s41418-022-00936-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-022-00936-x</ArticleId><ArticleId IdType="pmc">PMC8782710</ArticleId><ArticleId IdType="pubmed">35066575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundura L, Gimenez S, Cezar R, Andre S, Younas M, Lin YL, et al. . Angiotensin II induces reactive oxygen species, DNA damage, and T cell apoptosis in severe COVID-19. J Allergy Clin Immunol (2022) 150 (3):594&#x2013;603.e2. doi:&#xa0;10.1016/j.jaci.2022.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.06.020</ArticleId><ArticleId IdType="pmc">PMC9278992</ArticleId><ArticleId IdType="pubmed">35841981</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrati C, Sacchi A, Tartaglia E, Vergori A, Gagliardini R, Scarabello A, et al. . The role of P-selectin in COVID-19 coagulopathy: an updated review. Int J Mol Sci (2021) 22 (15):7942. doi: 10.3390/ijms22157942</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22157942</ArticleId><ArticleId IdType="pmc">PMC8348106</ArticleId><ArticleId IdType="pubmed">34360707</ArticleId></ArticleIdList></Reference><Reference><Citation>Odak I, Barros-Martins J, Bosnjak B, Stahl K, David S, Wiesner O, et al. . Reappearance of effector T cells is associated with recovery from COVID-19. EBioMedicine (2020) 57:102885. doi: 10.1016/j.ebiom.2020.102885</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102885</ArticleId><ArticleId IdType="pmc">PMC7338277</ArticleId><ArticleId IdType="pubmed">32650275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang CK, Han GC, Kim M, Kim G, Shin HM, Song KH, et al. . Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity. Int J Infect Dis (2020) 97:313&#x2013;21. doi: 10.1016/j.ijid.2020.05.106</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.05.106</ArticleId><ArticleId IdType="pmc">PMC7261468</ArticleId><ArticleId IdType="pubmed">32492530</ArticleId></ArticleIdList></Reference><Reference><Citation>Beserra DR, Alberca RW, Branco A, de Mendonca Oliveira L, de Souza Andrade MM, Gozzi-Silva SC, et al. . Upregulation of PD-1 expression and high sPD-L1 levels associated with COVID-19 severity. J Immunol Res (2022) 2022:9764002. doi: 10.1155/2022/9764002</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/9764002</ArticleId><ArticleId IdType="pmc">PMC9375698</ArticleId><ArticleId IdType="pubmed">35971391</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez FO, Combes TW, Orsenigo F, Gordon S. Monocyte activation in systemic Covid-19 infection: Assay and rationale. EBioMedicine (2020) 59:102964. doi: 10.1016/j.ebiom.2020.102964</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102964</ArticleId><ArticleId IdType="pmc">PMC7456455</ArticleId><ArticleId IdType="pubmed">32861199</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S, Jiang Y, Wei X, Liu X, Guan J, Chen Y, et al. . Dynamic changes in monocytes subsets in COVID-19 patients. Hum Immunol (2021) 82:170&#x2013;6. doi: 10.1016/j.humimm.2020.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2020.12.010</ArticleId><ArticleId IdType="pmc">PMC7762835</ArticleId><ArticleId IdType="pubmed">33531264</ArticleId></ArticleIdList></Reference><Reference><Citation>Andre S, Azarias da Silva M, Picard M, Alleaume-Buteau A, Kundura L, Cezar R, et al. . Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients. Cell Death Dis (2022) 13:741. doi: 10.1038/s41419-022-05190-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-05190-0</ArticleId><ArticleId IdType="pmc">PMC9419645</ArticleId><ArticleId IdType="pubmed">36030261</ArticleId></ArticleIdList></Reference><Reference><Citation>Soy M, Atag&#xfc;nd&#xfc;z P, Atag&#xfc;nd&#xfc;z I, Sucak GT. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic. Rheumatol Int (2021) 41:7&#x2013;18. doi: 10.1007/s00296-020-04636-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04636-y</ArticleId><ArticleId IdType="pmc">PMC7315691</ArticleId><ArticleId IdType="pubmed">32588191</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsilingiris D, Vallianou NG, Karampela I, Christodoulatos GS, Papavasileiou G, Petropoulou D, et al. . Laboratory findings and biomarkers in long COVID: what do we know so far? Insights into epidemiology, pathogenesis, therapeutic perspectives and challenges. Int J Mol Sci (2023) 24 (13):10458. doi: 10.3390/ijms241310458</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241310458</ArticleId><ArticleId IdType="pmc">PMC10341908</ArticleId><ArticleId IdType="pubmed">37445634</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol (2023) 23 (10):618&#x2013;34. doi:&#xa0;10.1038/s41577-023-00904-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Padron GT, Hernandez-Trujillo VP. Autoimmunity in primary immunodeficiencies (PID). Clin Rev Allergy Immunol (2023) 65:1&#x2013;18. doi: 10.1007/s12016-022-08942-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-022-08942-0</ArticleId><ArticleId IdType="pubmed">35648371</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P. Inflammation in atherosclerosis. Nature (2002) 420:868&#x2013;74. doi: 10.1038/nature01323</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01323</ArticleId><ArticleId IdType="pubmed">12490960</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell C, Kandalgaonkar MR, Golonka RM, Yeoh BS, Vijay-Kumar M, Saha P. Crosstalk between gut microbiota and host immunity: impact on inflammation and immunotherapy. Biomedicines (2023) 11 (2):294. doi: 10.3390/biomedicines11020294</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11020294</ArticleId><ArticleId IdType="pmc">PMC9953403</ArticleId><ArticleId IdType="pubmed">36830830</ArticleId></ArticleIdList></Reference><Reference><Citation>de Baat A, Trinh B, Ellingsgaard H, Donath MY. Physiological role of cytokines in the regulation of mammalian metabolism. Trends Immunol (2023) 44:613&#x2013;27. doi: 10.1016/j.it.2023.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2023.06.002</ArticleId><ArticleId IdType="pubmed">37423882</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow EK, Razani B, Cheng G. Innate immune system regulation of nuclear hormone receptors in metabolic diseases. J Leukoc Biol (2007) 82:187&#x2013;95. doi: 10.1189/jlb.1206741</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1206741</ArticleId><ArticleId IdType="pubmed">17314330</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>